Subsequent exploration indicated that an enhanced immunotherapeutic response rate was also found in RELN-mutated NSCLC patients (66.7% vs. 29.9%, Fisher exact test p = 0.009; Figure 3C). The gene discussed is RELN; the disease is non-small cell lung carcinoma.